Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Deferred Revenue: 2016-2022

Historic Current Deferred Revenue for Fortress Biotech (FBIO) over the last 3 years, with Dec 2022 value amounting to $728,000.

  • Fortress Biotech's Current Deferred Revenue fell 73.11% to $547,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $547,000, marking a year-over-year decrease of 73.11%. This contributed to the annual value of $728,000 for FY2022, which is 72.12% down from last year.
  • Fortress Biotech's Current Deferred Revenue amounted to $728,000 in FY2022, which was down 72.12% from $2.6 million recorded in FY2021.
  • In the past 5 years, Fortress Biotech's Current Deferred Revenue registered a high of $2.6 million during FY2021, and its lowest value of $728,000 during FY2022.
  • Its 2-year average for Current Deferred Revenue is $1.7 million, with a median of $1.7 million in 2021.
  • Data for Fortress Biotech's Current Deferred Revenue shows a maximum YoY plummeted of 72.12% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then tumbled by 72.12% to $728,000 in 2022.